Virologic and Immunologic Outcomes in Patients Switched from Amprenavir to Fosamprenavir in a Clinical Practice Setting
- *Corresponding Author:
- Dr. Gary E. Pakes
U.S. Collaborative Studies, ID MDC-HIV
GlaxoSmithKline, 5 Moore Drive
Research Triangle Park
NC 27709, USA
E-mail: [email protected]
Received Date: October 04, 2010; Accepted Date: December 07, 2010; Published Date: December 08,2010
Citation: Gathe JC, Daquoiag B, Fuchs JE, Pakes GE (2010) Virologic and Immunologic Outcomes in Patients Switched from Amprenavir to Fosamprenavir in a Clinical Practice Setting. J AIDS Clinic Res 1: 109. doi:10.4172/2155-6113.1000109
Copyright: © 2010 Gathe JC, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
In a 24-week phase 4, non-randomized, open-label, single-arm study, 19 HIV-infected patients receiving amprenavir (APV)-based highly active antiretroviral therapy (HAART) for 1.3-4.2 years (mean, 3.1 years) were switched to equimolar fosamprenavir (FPV) doses with no other changes in their treatment regimens. Most patients (74%) received APV/ ritonavir 600mg/100mg twice daily at screening. All but one were switched to FPV/ritonavir 700mg/100mg twice daily. Between baseline and week 24 after switching, clinical status generally remained stable or improved: median viral load 751 vs 71 copies/mL; CD4+ count 570 vs 622/mm3; proportion with viral load <400 copies/mL 47% vs 71%, and <50 copies/mL, 32% vs 35%. In 13 patients whose baseline HIV-1 RNA was >50 copies/mL, eight remained at this level and three were below it at week 24 (the other two were lost to follow-up). No study drug-related adverse events were reported and laboratory values did not notably change.